Mode
Text Size
Log in / Sign up

Structured narrative review suggests Dahuang Zhechong Pill may improve vascular markers in lower extremity peripheral artery disease

Structured narrative review suggests Dahuang Zhechong Pill may improve vascular markers in lower…
Photo by Gabriel Mihalcea / Unsplash
Key Takeaway
Consider Dahuang Zhechong Pill for lower extremity peripheral artery disease with cautious optimism regarding vascular markers.

This structured narrative review examines the potential role of Dahuang Zhechong Pill in managing lower extremity peripheral artery disease. The scope includes a synthesis of data from mostly small-sample trials and limited clinical reports. The authors distinguish in silico findings as hypothesis-generating evidence separate from in vitro or in vivo studies.

Key synthesized findings indicate improvements in ankle–brachial index, lipid profiles, blood viscosity, and microcirculatory perfusion. Specific effect sizes, absolute numbers, and p-values were not reported in the source material. Secondary outcomes such as endothelial-related readouts, lipid metabolism, inflammation, oxidative stress, and hemorheological parameters were also assessed but lacked quantitative detail.

The review notes limitations including mostly small-sample trials and limited clinical reports. Safety signals were generally favorable short-term, with serious adverse events, discontinuations, and specific tolerability data not reported. Funding or conflicts of interest were not reported. The authors suggest standardized clinical use and potential international application while maintaining caution due to the study phase being not reported and the overall evidence certainty being not reported.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Lower extremity peripheral artery disease (PAD) is a chronic ischemic disorder primarily driven by atherosclerosis (AS) and characterized by endothelial injury, lipid deposition, inflammation, oxidative stress, and hemorheological abnormalities. From the perspective of traditional Chinese medicine (TCM), its pathogenesis is commonly interpreted within the concept of “Tuoju”, in which blood stasis obstructs the collaterals/meridians and may coexist with qi deficiency, blood heat, or phlegm-dampness. Dahuang Zhechong Pill (DHZCP), first recorded in the Jingui Yaolue, is traditionally prescribed to remove blood stasis, clear heat, and resolve masses, while also supporting vital qi and nourishing yin, which conceptually aligns with TCM pattern differentiation in PAD. Preclinical studies and limited clinical reports suggest that DHZCP may be associated with multi-domain effects relevant to PAD pathophysiology, including endothelial-related readouts, lipid metabolism, inflammation, oxidative stress, and hemorheological parameters. Clinical studies (mostly small-sample trials) indicate that DHZCP may be associated with improvements in ankle–brachial index (ABI), lipid profiles, blood viscosity, and microcirculatory perfusion, particularly when used as an adjunct to acupuncture, blood-activating prescriptions, or conventional therapies, with generally favorable short-term safety signals. This review summarizes the traditional rationale and modern evidence on DHZCP for PAD, critically appraises the current evidence base and its limitations, and proposes priorities for future research to support standardized clinical use and potential international application. This article is a structured narrative review based on a predefined literature search and study selection strategy. In silico findings (e.g., network approaches and molecular docking) are treated as hypothesis-generating evidence and are clearly distinguished from in vitro/in vivo and clinical studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.